ABCA1 and glomerulosclerosis: Preclinical validation comes from animal models, where podocyte-specific Abca1 knockout exacerbates glomerulosclerosis, whereas treatment with ABCA1 agonists like cyclodextrin ameliorates DKD pathology (14).